METHODS AND SYSTEMS FOR FUNCTIONAL MATURATION OF iPSC AND ESC DERIVED CARDIOMYOCYTES
US-2024076619-A1 · Mar 7, 2024 · US
US9506031B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9506031-B2 |
| Application number | US-201414563459-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 8, 2014 |
| Priority date | Oct 22, 2004 |
| Publication date | Nov 29, 2016 |
| Grant date | Nov 29, 2016 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Disclosed herein are methods and materials for producing a more developmentally potent cell from a less developmentally potent cell. Specifically exemplified herein are methods that comprise introducing an expressible dedifferentiating polynucleotide sequence into a less developmentally potent cell, wherein the transfected less developmentally potent cell becomes a more developmentally potent cell capable of differentiating to a less developmentally potent cell of its lineage of origin or a different lineage.
Opening claim text (preview).
What is claimed is: 1. A mesenchymal stem cell possessing increased developmental potency, said mesenchymal stem cell produced by introducing into said mesenchymal stem cell at least one polynucleotide comprising coding regions for oct4 and sox2, wherein expression of said coding regions causes an increase of nanog in the mesenchymal stem cell, and wherein said expression results in higher developmental potency of said mesenchymal stem cell. 2. A cell produced by a method comprising introducing into a mesenchymal cell at least one polynucleotide encoding oct4 and at least one polynucleotide encoding sox2.
for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title
Nanog · CPC title
from mesenchymal stem cells · CPC title
Genetically modified cells · CPC title
Bone marrow mesenchymal stem cells (BM-MSC) · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.